EDITEditas Medicine, Inc.
$2.83-28% 1Y
$2.83
$1.6652 weeks$4.15
The financials
Editas Medicine, Inc. by the numbers
Editas Medicine, Inc. (EDIT) reported revenue of $12M in Q2 2026 (quarter ended Jun 30, 2026), up 232% from the same quarter a year earlier. That came with net loss of $18M. For the full year FY2025, revenue was $41M (+25% year on year) and net income −$160M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $12M | $3.6M | +232% |
| Operating income | −$19M | −$52M | n/a |
| Net income | −$18M | −$53M | n/a |
| Diluted EPS | −$0.15 | −$0.63 | n/a |